H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki- 67 expression

American Journal of Pathology

Volumn 153, Issue 5, 1998, Pages 1597-1607

  Adriaenssens, Eric ^a   Dumont, Lionel ^a   Lottin, Séverine ^a   Bolle, Domitille ^a   Leprêtre, Alain ^b   Delobelle, Alice ^c   Bouali, Fatima ^c   Dugimont, Thierry ^a,d   Coll, Jean ^c   Curgy, Jean Jacques ^a,b  

^a Centre de Biologie Cellulaire   (France)

^b UNIV LILLE   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

^d Faculte des Sciences Jean Perrin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER;

ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ARTICLE; BREAST ADENOCARCINOMA; CANCER GRADING; CELL CYCLE; GENE DELETION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE; POINT MUTATION; PRIORITY JOURNAL; RNA ANALYSIS;

EID: 18544405060     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65748-3     Document Type: Article

References (111)

1. Pachnis V, Belayev A, Tilghman SM: Locus unlinked to α-fetoprotein under the control of the murine raf and Rif genes. Proc Natl Acad Sci USA 1984, 81:5523-5527
2. Poirier F, Chan CTJ, Timmons PM, Robertson EJ, Evans MJ, Rigby PWJ: The murine H19 gene is activated during embryonic stem cell differentiation in vitro at the time of implantation in the developing embryo. Development 1991, 113:1105-1114
3. Rachmilevitz J, Goshen R, Ariel I, Schneider T, de Groot N, Hochberg A: Parental imprinting of the H19 gene. FEBS Lett 1992, 309: 25-28
4. Douc-Razy S, Coll J, Barrois M, Joubel A, Prost S, Dozier C, Stéhelin D, Riou G: Expression of the human fetal BAC/H19 gene in invasive cancers. Int J Oncol 1993, 32:753-758
5. Lustig O, Ariel I, Ilian J, Lev-Lehman E, de Groot N, Hochberg A: Expression of the imprinted gene H19 in the human fetus. Mol Reprod Dev 1994, 38:239-246
6. Dugimont T, Curgy JJ, Wernert N, Delobelle A, Raes MB, Joubel A, Stéhelin D, Coll J: The H19 gene is expressed within both epithelial and stromal components of human invasive adenocarcinomas. Biol Cell 1995, 85:117-124
7. Pachnis V, Brannan CI, Tilghman SM: The structure and expression of a novel gene activated in early mouse embryogenesis. EMBO J 1988, 7:673-681
8. Leibovitch M, Nguyen V, Gross M, Solhonne B, Leibovitch S, Bernheim A: The human ASM (adult skeletal muscle) gene: expression and chromosomal assignment to 11p15. Biochem Biophys Res Commun 1991, 180:1241-1250
9. Zhang Y, Tycko B: Monoallelic expression of the human H19 gene. Nature Genet 1992, 1:40-44
10. Han DKM, Liau G: Identification and characterization of developmentally regulated genes in vascular smooth muscle cells. Circulation Res 1992, 71:711-719
11. Brannan CI, Dees EC, Ingram RS, Tilghman SM: The product of the H19 gene may function as an RNA. Mol Cell Biol 1990, 10:28-36
12. Joubel A, Curgy JJ, Pelczar H, Bègue A, Lagrou C, Stéhelin D, Coll J: The 5′ part of the human H19 RNA contains cis-acting elements hampering its translatability. Cell Mol Biol 1996, 42:1159-1172
13. Bartolomei MS, Zemel S, Tilghman SM: Parental imprinting of the mouse H19 gene. Nature 1991, 351:153-155
14. Feinberg AP: Genomic imprinting and gene activation in cancer. Nature Genet 1993, 4:110-113
15. Mannens M, Slater RM, Heyting C, Bliek J, De Kraker J, Coad N, De Pagter-Holthuizen P, Pearson PL: Molecular nature of genetic changes resulting in loss of heterozygosity of chromosome 11 in Wilms' tumours. Hum Genet 1988, 81:41-48
16. Reeve AE, Sih SA, Raizis AM, Feinberg AP: Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumor cells. Mol Cell Biol 1989, 9:1799-1803
17. Tycko B: Genomic imprinting: mechanism and role in human pathology. Am J Pathol 1994, 144:431-443
18. Skinner MA, Vollmer R, Huper G, Abbott P, Inglehart JD: Loss of heterozygosity for genes on 11p and the clinical course of patients with lung carcinoma. Cancer Res 1990, 50:2303-2306
19. Fujimori M, Tokino T, Hino O, Kitagawa T, Imamura T, Okamoto E, Mitsunobu M, Ishikawa T, Nakagama H, Harada H: Allelotype study of primary hepatocellular carcinoma. Cancer Res 1991, 51:89-93
20. Ali IU, Lidereau R, Theillet C, Callahan R: Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. Science 1987, 238:185-188
21. Ehlen T, Dubeau L: Loss of heterozygosity on chromosomal segments 3p, 6q and 11p in human ovarian carcinomas. Oncogene 1990, 5:219-223
22. Reeve AE: Role of genomic imprinting in Wilms' tumour and over-growth disorders. Med Pediatr Oncol 1996, 27:470-475
23. Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, Smith PJ, Reeve AE: Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumor. Nature 1993, 362:749-751
24. Rainier S, Jonhson L, Dobry C, Ping A, Gundry P, Feinberg AP: Relaxation of imprinting genes in human cancer. Nature 1993, 362: 747-749
25. Leighton PA, Ingram RS, Eggenschwiller J, Efstratiadis A, Tilghman SM: Disruption of imprinting caused by deletion of the H19 gene region in mice. Nature 1995, 375:34-39
26. Leighton PA, Saam JR, Ingram RS, Stewart CL, Tilghman SM: An enhancer deletion affects both H19 and Igf2 expression. Genes Dev 1995, 9:2079-2089
27. Moulton T, Crenshaw T, Hao Y, Moosikasuwan J, Lin N, Dembitzer F, Hensle T, Weiss L, McMorrow L, Loew T, Kraus W, Gerald W, Tycko B: Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nature Genet 1994, 7:440-447
28. Steenman MJ, Rainier S, Dobry CJ, Grundy P, Horon IL, Feinberg AP: Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nature Genet 1994, 7:433-439
29. Taniguchi T, Sullivan MJ, Ogawa O, Reeve AE: Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms' tumor. Proc Natl Acad Sci USA 1995, 92:2159-2163
30. Cui H, Hedborg F, He L, Nordenskjöld A, Sandstedt B, Pfeifer-Ohlsson S, Ohlsson R: Inactivation of H19, an imprinted and putative tumor represser gene, is a preneoplastic event during Wilms' tumorigenesis. Cancer Res 1997, 57:4469-4473
31. Okamoto K, Morison IM, Taniguchi T, Reeve AE: Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis. Proc Natl Acad USA 1997, 94:5367-5371
32. Kondo M, Suzuki H, Ueda R, Osada H, Takagi K, Takahashi T: Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene 1995, 10: 1193-1198
33. Zhan S, Shapiro DN, Helman LJ: Activation of the imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 1994, 94:445-448
34. Zhan S, Shapiro D, Zhan S, Zhang L, Hirschfeld S, Elassal J, Helman L: Concordant loss of imprinting of the human insulin-like growth factor II gene promoters in cancer. J Biol Chem 1995, 270:27983-27986
35. Casola S, Pedone P V, Cavazzana AO, Basso G, Luksch R, d'Amore ESG, Carli M, Bruni CB, Riccio A: Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma. Oncogene 1997, 14:1503-1510
36. Rainier S, Dobry CJ, Feinberg AP: Loss of imprinting in hepatoblastoma. Cancer Res 1995, 55:1836-1838
37. Van Gurp RJHLM, Wolter Oosterhuis J, Kalscheuer V, Mariman ECM, Looijenga LHJ: Biallelic expression of the H19 and IGF2 genes in human testicular germ cell tumors. J Natl Cancer Inst 1994, 86:1070-1075
38. Elkin M, Shevelev A, Schulze E, Tykocinsky M, Cooper M, Ariel I, Pode D, Kopf E, de Groot N, Hochberg A: The expression of the imprinted H19 and IGF-2 genes in human bladder carcinoma. FEBS Lett 1995, 374:57-61
39. Douc-Razy S, Barrois M, Fogel S, Ahomadegbe JC, Stehelin D, Coll J, Riou G: High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas: uncoupling of H19 and IGF2 expression and biallelic hypomethylation of H19. Oncogene 1996, 12:423-430
40. Hibi K, Nakamura H, Hirai A, Fujikase Y, Kasai Y, Akiyama S, Ito K, Takagi H: Loss of imprinting in esophageal cancer. Cancer Res 1996, 56:480-482
41. Wada M, Seeger RC, Mizoguchi H, Kœffer HP: Maintenance of normal imprinting of H19 and Igf-2 genes in neuroblastoma. Cancer Res 1995, 55:3386-3388
42. Uyeno S, Aoki Y, Nata M, Sagisaka K, Kayama T, Yoshimoto T, Ono T: Igf-2 but not H19 shows loss of imprinting in human glioma. Cancer Res 1996, 56:5356-5359
43. Vu TH, Yballe C, Boonyanit S, Hoffman AR: Insulin-like growth factor II in uterine smooth-muscle tumors: maintenance of genomic imprinting in leiomyomata and loss of imprinting in leiomyosarcomata. J Clin Endocrinol 1995, 80:1670-1676
44. Yballe C, Vu TH, Hoffman AR: Imprinting and expression of insulin-like growth factor-II and H19 in normal breast tissue and breast tumor. J Clin Endocrinol Metab 1996, 81:1607-1612
45. Ariel I, Lustig O, Schneider T, Pizov G, Sappir M, de-Groot N, Hochberg A: The imprinted H19 gene as a tumor marker in bladder carcinoma. Urology 1994, 45:335-338
46. Cooper MJ, Fischer M, Komitowski D, Shevelev A, Schulze E, Ariel I, Tykocinski ML, Miron S, Ilan J, de Groot N, Hochberg A: Developmentally imprinted genes as markers for bladder tumor progression. J Urol 1996, 155:2120-2127
47. Liu J, Kahri A, Heikkilä P, Ilvesmäki V, Voutilainen R: H19 and insulin-like growth factor-II gene expression in adrenal tumors and cultured adrenal cells. J Clin Endocrinol Metab 1995, 80:492-496
48. Walsh C, Miller SJ, Flam F, Fisher RA, Ohlsson R: Paternally derived H19 is differentially expressed in malignant and nonmalignant trophoblast. Cancer Res 1995, 55:1111-1116
49. Hao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B: Tumor suppressor activity of H19 RNA. Nature 1993, 365:764-767
50. Reid LH, West A, Gioli DG, Phillips KK, Kelleher KF, Arauja D: Localization of tumor suppressor gene in 11p15.5 using the G401 Wilms' tumor assay. Hum Mol Genet 1996, 5:239-247
51. Ariel I, Ayesh S, Perlman EJ, Pizov G, Tanos V, Schneider T, Erdmann VA, Podeh D, Komitowski D, Quasem AS, de Groot N, Hochberg A: The product of the imprinted H19 gene is an oncofetal RNA. J Clin Pathol 1997, 50:34-44
52. Verkerk AJMH, Ariel I, Dekker MC, Schneider T, van Gurp RJHLM, de Groot N, Gilly AJM, Oosterhuis JW, Hochberg AA, Looijenga LHJ: Unique expression patterns of H19 in human testicular cancers of different etiology. Oncogene 1997, 14:95-107
53. Lustig-Yariv O, Schulze E, Komitowski D, Erdmann V, Schneider T, de Groot N, Hochberg A: The expression of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines. Is H19 a tumor suppressor gene? Oncogene 1997, 15:169-177
54. Koi M, Johnson LA, Kalikin LM, Little PFR, Nakamura Y, Feinberg AP: Tumor cell growth arrest caused by subchromosomal transfectable DNA fragments from chromosome 11. Science 1993, 260:361-364
55. kip2, a structurally distinct member of the p21cip1 cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995, 9:650-662
56. kip2, on chromosome 11p15. Proc Natl Acad Sci USA 1996, 93:3026-3030
57. Chung WY, Yuan L, Feng L, Hensle T, Tycko B. Chromosome 11p15.5 regional imprinting: comparative analysis of KIP2 and H19 in human tissues and Wilms' tumors. Hum Mol Genet 1996, 5:1101-1108
58. KIP2 and its reduced expression in Wilms' tumors. Hum Mol Genet 1996, 5:783-788
59. Davis RL, Weintraub H, Lassar AB: Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 1987, 51:987-1000
60. Kim D, Zhang L, Dzau VJ, Pratt RE: H19, a developmentally regulated gene, is reexpressed in rat vascular smooth muscle cells after injury. J Clin Invest 1994, 93:355-360
61. Eversole-Cire P, Ferguson-Smith AC, Surani MA, Jones PA: Coordinate regulation of Igf-2 and H19 in cultured cells. Cell Growth Differ 1995, 6:337-345
62. Voutilainen R, Ilvesmäki V, Ariel I, Rachmilevitz J, de Groot N, Hochberg A: Parallel regulation of parentally imprinted H19 and IGF-II genes in cultured human fetal adrenal cells. Endocrinology 1994, 134:2051-2056
63. Leibovitch MP, Solhonne B, Guiller M, Verelle P, Leibovitch SA: Direct relationship between the expression of tumor suppressor H19 mRNA and c-mos proto-oncogene during myogenesis. Oncogene 1995, 10:251-260
64. Fernig DG, Smith JA, Rudland PS: Relationship of growth factors and differentiation in normal and neoplastic development of the mammary gland. Regulatory Mechanisms in Breast Cancer. Edited by Lippman M, Dickson R. Boston, Kluwer Academic Publishers, 1991, pp 47-77
65. Rudland PS, Barraclough R, Fernig DG, Smith JA: Mammary stem cells in normal development and cancers. Stem Cells and Cancer. Academic Press, 1997, pp 147-232
66. Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 1957, 11:359-377
67. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M: Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR): an improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989, 64:1914-1921
68. Balaton AJ, Ochando F, Painchaud MH: Utilisation des micro-ondes pour aviver ou restaurer les antigènes avant la réaction immunohistochimique. Ann Pathol 1993, 13:188-189
69. Quéva C, Ness SA, Grässer FA, Graf T, Vandenbunder B, Stéhelin D: Expression patterns of c-myb and v-myb induced myeloid-1 (mim-1) gene during the development of the chick embryo. Development 1992, 114:125-133
70. Siegel S (editor): Nonparametric Statistics for the Behavioral Sciences. London, McGraw-Hill, 1956
71. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992, 168: 357-363
72. McCormick D, Chong H, Hobbs C, Hall PA: Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB-1. Histopathology 1993, 22:355-360
73. Soon Lee C: Differences in cell proliferation and prognostic significance of proliferating cell nuclear antigen and Ki-67 antigen immunoreactivity in in situ and invasive carcinomas of the extrahepatic biliary tract. Cancer 1996, 78:1881-1887
74. Moll UM, Riou G, Levine AJ: Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992, 89:7262-7266
75. Spanakis E, Brouty-Boyé D: Quantitative variation of proto-oncogene and cytokine gene expression in isolated breast fibroblasts. Int J Cancer 1995, 61:698-705
76. Santen RJ, Martel J, Hoagland M: Stromal spindle cells contain aromatase in human breast tumors. J Clin Endocrinol Metab 1994, 79:627-632
77. Rønnov-Jessen L, Petersen OW, Koteliansky VE, Bissel MJ: The origin of myofibroblasts in breast cancer. J Clin Invest 1995, 95:859-873
78. Schurch W, Seemayer T, Gabbiani G: Myofibroblast. New York, Raven Press, 1992, pp 109-144
79. Tuck AB, Park M, Sterns EE, Boag A, Elliot BE: Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 1996, 148:225-232
80. Delannoy-Courdent A, Fauquette W, Dong-Le Bourhis XF, Boilly B, Vandenbunder B, Desbiens X: Expression of c-ETS-1 and uPA genes is associated with mammary epithelial cell tubulogenesis or neoplastic scattering. Int J Dev Biol 1996, 40:1097-1108
81. Van Roozendaal CEP, Klijn JGM, Sieuwertts AM, Henzen-Logmans SC, Foekens JA: Role of urokinase plasminogen activator in human breast cancer: active involvement of stromal fibroblasts. Fibrinolysis 1996, 10:79-83
82. Wang TN, Qian X, Granick MS, Solomon MP, Rothman VL, Berger DH, Tuszynski GP: Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor. Surgery 1996, 120:449-454
83. Vrana JA, Stang MT, Grande JP, Getz MJ: Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor-β family. Cancer Res 1996, 56:5063-5070
84. Sasano H, Frost AR, Saitoh R, Harada N, Poutanen M, Vihko R, Bulun SE, Silverberg SG, Nagura H: Aromatase and 17β-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J Clin Endocrinol Metab 1996, 81:4042-4046
85. Singer C, Rasmussen A, Smith HS, Lippman ME, Lynch HT, Cullen KJ: Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res 1995, 55:2448-2454
86. Van den Hoff A: Stromal involvement in malignant growth. Adv Cancer Res 1988, 50:159-196
87. Clarke R, Dickson RB, Lippman ME: Hormonal aspects of breast cancer: growth factors, drugs and stromal interactions. Crit Rev Oncol Hematol 1992, 12:1-23
88. Ellis MJC, Singer C, Hornby A, Rasmussen A, Cullen KJ: Insulin-like growth factor mediated stromal interactions in human breast cancer. Breast Cancer Res Treat 1994, 31:249-261
89. Dickson RB, Lippman ME: Growth factors in breast cancer. Endocrinol Res 1995, 16:559-589
90. Mentzel T, Fletcher CDM: The emerging role of myofibroblasts in soft tissue neoplasia. Am J Clin Pathol 1996, 107:2-5
91. Han DKM, Khaing ZZ, Pollock RA, Haudenschild CC, Liau G: H19, a marker of developmental transition, is reexpressed in human atherosclerotic plaques and is regulated by the insulin family of growth factors in cultured rabbit smooth muscle cells. J Clin Invest 1996, 97:1276-1285
92. Grévin D, Chen JH, Raes MB, Stéhelin D, Vandenbunder B, Desbiens X: Involvement of the proto-oncogene c-ets-1 and the urokinase plasminogen activator during mouse implantation and placentation. Int J Dev Biol 1993, 37:519-529
93. Wernert N, Gilles F, Fafeur V, Bouali F, Raes MB, Pyke C, Dupressoir T, Seitz G, Vandenbunder B, Stéhelin D: Stromal expression of c-ets-1 transcription factor correlates with tumor invasion. Cancer Res 1994, 54:5683-5688
94. Isfort RJ, Kerckaert GA, Tycko B, LeBoeuf RA: Role of the H19 gene in Syrian hamster embryo cell tumorigenicity. Mol Carcinog 1997, 20:189-193
95. Görlich M, Jandrig B: Estradiol receptors and metastasis in human breast cancers. Folia Histol (Prague) 1996, 42:3-10
96. O'Neill JS, Elton RA, Miller WR: Aromatase activity in adipose tissue from breast quadrants: a link with tumor site. Br Med J 1988, 296: 741-743
97. Bulun SE, Price TM, Mahendroo MS, Aitken J, Simpson ER: A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 1993, 77:1622-1628
98. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER: Estrogen biosynthesis proximal to a breast tumor is stimulated by PEG2 via cyclic AMP, leading to activation of promoter of the CYP19 aromatase gene. Endocrinology 1996, 137:5739-5742
99. Simpson ER, Bulun SE, Nichols JE, Zhao Y: Estrogen biosynthesis in adipose tissue: regulation by paracrine and autocrine mechanisms. J Endocrinol 1996, 150:51-57
100. Adriaenssens E, Dumont L, Fauquette W, Le Bourhis X, Dugimont T, Coll J, Curgy JJ: Modulations of the H19 gene expression in normal or malignant mammary epithelial cells. Biol Cell 1996, 88:80a
101. Crowford LV, Pim DC, Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982, 30:403-408
102. Barnes DM, Dublin EA, Fischer CJ, Levison DA, Millis RR: Immunohistological detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Human Pathol 1993, 24:200-206
103. Domalaga W, Harezga B, Szadowska A, Markiewski M, Weber K, Osborn M: Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. Am J Pathol 1993, 142:669-674
104. Hurlimann J: Prognostic value of p53 protein expression in breast carcinomas. Pathol Res Pract 1993, 198:996-1003
105. Silvestrini R, Benini E, Davidone MG: p53 as an independent prognosis marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993, 965-970
106. Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD, Pearl FF: P53 gene mutations and steroid receptor status in breast cancer: clinicopathological correlations and prognostic assessment. Cancer 1994, 73:2147-2156
107. Barbareschi M: Prognostic value of the immunohistochemical expression of p53 in breast carcinomas: a review of the literature involving over 9,000 patients. Appl Immunohistochem 1996, 4:106-116
108. Dugimont T, Montpellier C, Adriaenssens E, Lottin S, Dumont L, Iotsova V, Lagrou C, Stéhelin D, Coll J, Curgy JJ: The H19 TATA-less promoter is efficiently repressed by the wild-type tumor suppressor gene product p53. Oncogene 1998, 16:2395-2401
109. Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams KE, Turbett GR, House A, Iacopetta BJ: Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 1996, 27:1050-1055
110. Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983, 31:13-20
111. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984, 133:1710-1715